AMENDMENT UNDER 37 C.F.R. § 1.116

Application No.: 10/551,764

Attorney Docket No.: Q90374

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1. (currently amended): A polyethylene glycol (PEG)-polypeptide homodimer

complex, comprising

a first PEG molecule; and

two molecules of a polypeptide,

wherein the two molecules of the polypeptide are linked to each other via the first PEG

molecule to form a polypeptide-first PEG-polypeptide complex, and the polypeptides of the

polypeptide-first PEG-polypeptide complex each are bonded to a second PEG molecule having a

larger molecular weight than that of the first PEG molecule to form a second PEG-polypeptide-

first PEG-polypeptide-second PEG complex, the first and second PEG molecules having

molecular weights ranging from 2 to 20 kDa and from 20 to 40 kDa, respectively, and

wherein the first PEG molecule is covalently bonded to the polypeptides at an N-terminal

residue or athe C-terminal residue of the polypeptides.

2. (currently amended): The complex of claim 1, wherein the first PEG molecule is

covalently bonded to the respective N-terminal <u>residue</u> of the polypeptide molecules.

2

AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q90374

Application No.: 10/551,764

3. (previously presented): The complex of claim 1, wherein the second PEG

molecule is covalently bonded to an amino group of a lysine residue of the polypeptide

molecules.

4. (previously presented): The complex of claim 1, wherein the polypeptide is

selected from the group consisting of a human growth hormone, interferon, granulocyte colony

stimulating factor, granulocyte colony stimulating factor derivative having an amino acid

sequence wherein cysteine at position 17 is replaced with serine, erythropoietin, insulin,

interleukin, granulocyte macrophage colony stimulating factor, and tumor necrosis factor

receptor.

5. (previously presented): The complex of claim 1, wherein the first PEG molecule

has two aldehyde or propionic aldehyde groups at each end.

Claims 6-7. (canceled)

8. (previously presented): The complex of claim 1, wherein said second PEG

molecule has at one end a reactive group selected from the group consisting of succinimidyl

propionate, succinimidyl carboxymethyl, succinimidyl carbonate and maleimide.

3

AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q90374

Application No.: 10/551,764

9. (previously presented): The complex of claim 1, wherein said second PEG

molecule is linear or branched.

Claims 10 - 11 (canceled)

12. (withdrawn): A method for preparing the PEG-polypeptide homodimer complex

of claim 1, which comprises the steps of: (a) preparing a homodimer by connecting two

molecules of a physiologically active polypeptide via a PEG linker; and (b) modifying each of

the two molecules of the physiologically active polypeptide of the homodimer with one molecule

of PEG.

4